Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The article " Regeneron: Is It the Perfect Biotech Stock for Value and Growth? " first appeared on MarketBeat.

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...

Eylea sales rose just 1% YoY in 2024 as this ... Libtayo's year 2024 sales rose 40% YoY to $1.22 billion, which is its latest blockbuster just starting to accelerate. Libtayo received positive ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...

Although it often affects people later in life, it is not uncommon for people 40 and older to be affected ... such as Avastin, Lucentis, and Eylea. These drugs work by blocking VEGF, a protein that ...

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the Zacks Consensus Estimates. The company reported earnings of 50 cents per ...

He advocated for including gold in a diversified portfolio, particularly within a 60-40 asset allocation model ... of ...